The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6. It reported earnings in this window, a natural checkpoint for the thesis.
Kronos Worldwide, Inc.
KRO · the NYSE · USD · Market cap $879M · 2,263 employees
Kronos Worldwide, Inc.
PASS · Titan Ethical · score 70.0Price as of 29 Oct 2026Daily close, not a live quote
Screened 2026-10-29 · the tape above runs as of 02:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.45 USD at the 29 Oct 2026 close
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.20)
- Last reviewed29 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 7.45 against the desk's fair-value range, base estimate 6.84, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.20, read 2026-10-29
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Kronos Worldwide, Inc. holds its Accumulation at $7.45. The statistical read favours the sellers, held for 30 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 30 days |
| Price at the screen | $7.45 |
| Valuation | N/A trailing · 12.45 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.07 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 31.78% | Below 33% | Interest-bearing debt is just 31.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.10% | Below 33% | Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit. | Pass |
| Receivables | 16.73% | Below 49% | Money owed to the company is 16.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.06% | Below 5% | Only 0.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Kronos Worldwide, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 32%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KRO's ethical verdict changes
Today KRO passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-29 screen. The gold marker is the market price at the same screen. The price runs 8.2% above the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +14% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-29 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 12.4xfairly priced for its growth rate |
| EPS, trailing | -0.95 |
| EPS, forward | 0.61 |
| Revenue growth | +12.9%steady growth |
| Profit margin | -5.6%currently unprofitable |
| Return on equity | -13.7%not currently earning a positive return on equity |
| FCF yield | 11.83% |
| Dividend yield | 284.00% |
| Debt to equity | 0.78moderate, manageable leverage |
| Current ratio | 3.30comfortably covers its short-term bills |
| Beta | 1.07moves a little more than the market |
| Short interest, float | 0.05% |
| 52-week range | 4.08 - 9.17 |
| Market cap | $879M |
| Employees | 2,263 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeKRO trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 27.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 32% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (2 analysts) rates it none, with a mean price target of $6.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Kronos Worldwide Shares Surge 72% YTD: What's Driving the Rally? Yahoo Finance · 18d ago
- Is Kronos Worldwide (KRO) Stock Outpacing Its Basic Materials Peers This Year? Yahoo Finance · 18d ago
- The Zacks Analyst Blog Highlights Chime Financial, Marqeta and Kronos Yahoo Finance · 22d ago
- 3 Stocks With 100%+ Projected Q3 Earnings Growth to Buy Before Results Yahoo Finance · 22d ago
- Nutrien to Indefinitely Shut Down Trinidad Nitrogen Operations Yahoo Finance · 24d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $7.31 | -10.1% | $0.05 | $906 | -9.4% |
| 2 months | $6.56 | +0.1% | $0.05 | $1,009 | +0.9% |
| 3 months | $4.88 | +34.8% | $0.05 | $1,358 | +35.8% |
| 6 months | $4.83 | +36.0% | $0.10 | $1,381 | +38.1% |
| 1 year | $6.67 | -1.6% | $0.20 | $1,014 | +1.4% |
| 2 years | $12.76 | -48.5% | $0.59 | $561 | -43.9% |
| 3 years | $7.76 | -15.4% | $1.16 | $996 | -0.4% |
| 5 years | $11.90 | -44.8% | $2.66 | $775 | -22.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever KRO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.